With broad therapeutic scope
PharmNovo aims to develop novel drugs with superior clinical properties to treat patients with neuropathic pain.
Our lead compound PN6047 is a novel potent, selective and biased signalling delta opioid receptor agonist, which is predicted to reduce common symptoms of neuropathic pain and combat other conditions involving sensory hypersensitivity, including chronic cough and itch.
The drug candidate PN6047 also addresses another problem: neuropathic pain patients frequently suffer from associated anxiety and depression, which exacerbates their pain and generates a vicious cycle of low mood and increasing pain. DOR agonists can attenuate both pain and the associated emotional disorders.
In various pre-clinical studies, PN6047 has shown high selectivity and potency and very convincing efficacy in reducing neuropathic pain without any signs of the unwanted side effects of traditional opioids, such as respiratory depression, abuse potential and the development of tolerance.
PN6047 has an excellent pre-clinical safety profile and fully medicine-like properties predicting favourable dosing in humans.
PN6047 has fully druggable properties and characteristics enabling the production of a commercial solid dosage form.
The company's current focus is on demonstrating efficacy through Phase IIA Proof of Concept studies in one or more patient populations starting in 2026.
